About Us
Projects and Technology
Governance
Investors
Media
Contact

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

October 20, 2021

Extraordinary General Meeting 2021

The Extraordinary General Meeting was held on Wednesday, 20 October 2021.

Documents

Protokoll extra bolagsstämma 2021 – Oasmia Pharmaceutical AB
Svenska 20 oktober, 2021
Minutes Extraordinary General Meeting 2021 – Oasmia Pharmaceutical AB
Swedish October 20, 2021
Press release – Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB
English October 20, 2021
Proxy Form – Oasmia Pharamceutical AB
English September 20, 2021
Postal voting form – Oasmia Pharmaceutical AB
English September 20, 2021
Press release – Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
English September 20, 2021

Share this page

Calendar

August 12, 2025
Interim report Q2 2025
November 11, 2025
Interim report Q3 2025
February 12, 2026
Interim report Q4 2025

Corporate Governance

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

Take me there

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com